Astellas Pharma has looked outside of the box for its latest cancer drug development partnership, joining forces with Sony on a project to find new antibody-drug conjugate
AstraZeneca has looked to China for another antibody-drug conjugate (ADC) candidate for cancer, paying $55 million for rights to a preclinical candidate from Shanghai-base
Shares in ImmunityBio were in freefall today after it revealed the FDA had rejected its marketing application for Anktiva as a treatment for bladder cancer.
There have been calls for caution when it comes to the use of Pfizer’s respiratory syncytial virus (RSV) vaccine in pregnant women, ahead of an FDA advisory committee meet
Swedish Orphan Biovitrum (Sobi) has agreed a $1.7 billion merger deal to acquire CTI BioPharma and its recently-approved Vonjo drug for people with blood cancer myelofibro
Gilead Sciences has bulked up its early-stage R&D portfolio with an agreement to buy XinThera, adding drugs targeting PARP for oncology and MK2 for inflammatory diseas
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.